## **Lenalidomide Prescription Authorisation Form** Completion of this information is mandatory for ALL patients. A newly completed copy of this form must accompany EVERY lenalidomide prescription. The completed form should be retained in the pharmacy. Both signatures must be present prior to dispensing lenalidomide Name of treating hospital Patient date of birth DO MM YYYY Patient ID number/Initials: Prescriber's declaration As the Prescriber, I have read and understood the Healthcare Professional's Information Guide. I confirm the information provided on this PAF is accurate, complete and in accordance with the requirements of the Pregnancy Prevention Programme for lenalidomide. I confirm treatment has been initiated and is monitored under the supervision of a physician with expertise in managing immunomodulatory or chemotherapeutic agents. Prescriber: (print) Print Date Bleep Supervising physician name: (print) Indication Pharmacist's declaration Multiple myeloma (tick) I am satisfied that this Lenalidomide Prescription Authorisation Mantle cell lymphoma relapsed and/or Form has been completed fully and that I have read and refractory understood the Lenalidomide Healthcare Professional's Myelodysplastic syndromes with isolated Information Guide. For women of childbearing potential, the del5qcytogenetic abnormality dispensing will be taking place within 7 days of the date of Follicular lymphoma prescription. I am dispensing no more than a 4 week supply to Other (please specify) women of childbearing potential and 12 weeks for males and women of non-childbearing potential Capsule strength prescribed: (tick) 2.5mg□ 5mg□ 7.5mg 🗆 Print 10mg □ 15mg □ 20mg □ 25mg Bleep Quantity of Capsules prescribed: \* Name and postcode of dispensing pharmacy \* Do **NOT** enter number of packs Enter the cycle number(s) prescribed for this patient Woman of non-childbearing potential Yes □ No □ The patient has been counselled about the teratogenic risk of treatment Lenalidomide brand dispensed: with lenalidomide and understands the need to use a condom if involved in sexual activity with a woman of childbearing potential not using effective contraception or if their partner is pregnant (even if the patient has had a vasectomy). Yes □ No □ Note to pharmacist – Do not dispense unless ticked YES for Male patients Woman of childbearing potential The patient has been counselled about the teratogenic risk of treatment and the need to avoid pregnancy and has been on effective contraception for at least 4 weeks or committed to absolute and continuous abstinence confirmed on a monthly basis. Yes □ No □ Date of last negative pregnancy test: Note to pharmacist - Do not dispense unless ticked yes and a negative test has been conducted within 3 days prior to the prescription date and

Version 2 Feb 2024

dispensing is taking place within 7 days of the prescription date